Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Gansevoort, Ron T; van Gastel, Maatje D A; Chapman, Arlene B; Blais, Jaime D; Czerwiec, Frank S; Higashihara, Eiji; Lee, Jennifer; Ouyang, John; Perrone, Ronald D; Stade, Katrin; Torres, Vicente E; Devuyst, Olivier.
Kidney Int; 96(1): 159-169, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-30898339